Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IGF-Methotrexate Conjugate in Advanced Tumors
NCT02045368Phase 1Completed
- Sponsor
- IGF Oncology
- Start
- Jan 2014
- Primary completion
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of IGF-methotrexate conjugate in breast cancer, brain cancer, gastrointestinal cancer and 6 more, sponsored by IGF Oncology. Primary endpoint: Maximum Tolerated Dose at 30 days. Started Jan 2014; status: completed.
02
Drugs
IGF-methotrexate conjugate
03
Conditions
breast cancerbrain cancergastrointestinal cancergenitourinary cancergynecologic cancer
Beyond the preview
Go deeper on NCT02045368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02045368.